

underway in leukaemia and other tumours. These approaches, coupled with genome-wide analyses of alterations to DNA copy number and epigenetic phenomena, will lay bare the genome of acute lymphoblastic leukaemia, and allow us to identify logical pathways for therapeutic intervention in this disease.


Charles G Mullighan

St Jude Children's Research Hospital, Memphis, TN 38105, USA
charles.mullighan@stjude.org

I have been a speaker at and received travel funding for an Affymetrix symposium.

- 1 Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. *N Engl J Med* 2004; **350**: 1535-48.
- 2 Bercovich D, Ganmore I, Scott LM, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. *Lancet* 2008; published online Sept 20. DOI:10.1016/S0140-6736(08)61341-0.
- 3 Zwaan MC, Reinhardt D, Hitzler J, Vyas P. Acute leukemias in children with Down syndrome. *Pediatr Clin North Am* 2008; **55**: 53-70.
- 4 Arico M, Ziino O, Valsecchi MG, et al, for the Italian Association of Pediatric Hematology and Oncology (AIEOP). Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). *Cancer* 2008; **113**: 515-21.
- 5 Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. *Nat Rev Cancer* 2007; **7**: 673-83.
- 6 Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. *Science* 1997; **278**: 1309-12.
- 7 Malinge S, Ben-Abdelali R, Settegrana C, et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. *Blood* 2007; **109**: 2202-04.
- 8 Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. *Lancet* 1999; **354**: 1499-503.
- 9 Jeong EG, Kim MS, Nam HK, et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. *Clin Cancer Res* 2008; **14**: 3716-21.
- 10 Flex E, Petrangeli V, Stella L, et al. Somatic mutations of JAK1 in adult acute lymphoblastic leukemia. *J Exp Med* 2008; **205**: 751-58.
- 11 Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature* 2007; **446**: 758-64.
- 12 Lo KC, Chalker J, Strehl S, et al. Array comparative genome hybridization analysis of acute lymphoblastic leukaemia and acute megakaryoblastic leukaemia in patients with Down syndrome. *Br J Haematol* 2008; published online June 13. DOI:10.1111/j.1365-2141.2008.07280.x.

Education, crime and justice, and social welfare: call for papers



To submit a paper go to <http://ees.elsevier.com/thelancet/default.asp>

How can we improve our schools? How do we best protect our community from crime? How should we care for the homeless? As with health, there is an abundance of questions concerning the effectiveness of interventions and the balance between good and harmful effects, in education, crime and justice, and social welfare.

Together, these areas comprise much of what society is about: creating a safe environment for children to grow up in and encouraging learning and equal opportunities for all, while providing safety nets for those in need. As underlined by the Commission on Social Determinants of Health, education, protection from crime, and social welfare also clearly constitute the broader determinants of health. Action is needed outside of health care to improve life expectancy and health.¹

To underpin practice and policy development in education, crime and justice, and social welfare, and in public health, good evidence is needed. That is the focus of a joint conference hosted by The Campbell Collaboration and *The Lancet*, in Oslo, Norway, on May 18-19, 2009, to coincide with the annual Campbell Collaboration colloquium.

This conference on "Better evidence for a better world" especially welcomes contributions from low-income and

middle-income countries. To assess the effect of attempts to improve how people are born, grow, live, work, and age in poor countries is very important. We aim to show how the social and medical arenas inter-relate and how interventions often target the same individuals across disciplines. The conference will highlight the need for relevant and reliable evidence, and encourage the building of a world library of systematic reviews aimed at summarising that evidence. Hence we are interested in both primary research and systematic reviews.

The Lancet is especially interested in publishing research, reviews, and health-policy papers that will be presented at the conference, but will also consider other papers for a theme issue. Papers should be submitted online and the covering letter should mention that the submission is in response to this call for papers. The closing date for submissions is Dec 15, 2008.

*Arild Bjørndal, Richard Horton

Campbell Collaboration, Norwegian Knowledge Centre for the Health Services, N-0130 Oslo, Norway (AB); and *The Lancet*, London, UK (RH)
arb@nokc.no

- 1 Commission on Social Determinants of Health. Closing the gap in a generation: health equity through action on the social determinants of health. Geneva: World Health Organization, 2008.